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current regulation and practices; (4) Lack of an ICER threshold. The likely future of 
health economic assessment of drugs in France will imply the expansion of health 
economic assessment scope, the implementation of an impactful ICER threshold, 
the generalisability of coverage with evidence, and eventually the possible merge 
of the CEESP and the CT. ConClusions: Major steps in French HTA are expected 
to occur in the near future. Empowerment of the CEESP (merged or not with the 
CT) is expected, and it may become the unique or leading committee addressing 
the HTA of pharmaceuticals in France. However, it is likely that the robust and well-
established methodology developed by the CT (SMR, ASMR) to assess comparative 
efficacy or effectiveness will remain in force.
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objeCtives: The National Centre for Pharmacoeconomics (NCPE) reviews the 
cost effectiveness of new medicines following an application for reimbursement 
in Ireland. All medicines are subjected to a preliminary rapid review (RR, stated 
to take ~2 weeks) with only high cost products and those with significant budget 
impact subjected to formal pharmacoeconomic assessments (PEA, stated to be com-
pleted in < 3 months). This research aims to review all recent NCPE appraisals to 
determine what proportion of drugs require a full appraisal, the review times and 
rates of approvals. Methods: Publically available decision summaries from the 
NCPE were identified (from 1st January 2013 to 31st May 2015) and the outcome, 
date, indication, and whether a full PEA was needed were extracted. Results: 110 
appraisals were identified with 43% (47/110) approved following RR. Of these, only 
21% (10/47) were reviewed within < 2 weeks; the rest taking on average > 2x longer 
than stated (29 days). Of the 57% (63/111) appraisals deemed to require a full PEA, 
62% (39/63) were initiated, on average, > 5 months post-RR. Only 33% (13/39) of full 
PEAs were eventually recommended, adding another 5 months (average 152 days) 
to the process. 27% (30/110) appraisals were for oncology medicines; 90% (27/30) of 
which required a full PEA. Only 15 were NCPE-appraised, almost all of which were 
not recommended (87%, 13/15). ConClusions: The total average length of time 
between start of the RR to final PEA recommendation is up to a year (12 months), 
which is substantially longer than what is claimed. If companies can convince the 
NCPE that their medicine is not high cost, nor has a significant budget impact, the 
RR process can enable rapid reimbursement within 1-2 months. However, if a full 
PEA is required, this significantly delays reimbursement decisions, with positive 
recommendations being difficult to achieve, especially for oncology medicines.
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objeCtives: The Swedish Dental and Pharmaceutical Benefits Agency (TLV) make 
recommendations on whether outpatient prescription drugs should be publically 
reimbursed with cost-effectiveness being a key criterion. By contrast, no national 
economic assessment was traditionally implemented for hospital pharmaceuticals, 
which were typically individually appraised by each county council. However, since 
January 2011, a national co-ordinating group of Swedish county councils (NLT) can 
request that selected in-patient therapies undergo a health economic assessment 
by the TLV, on which the NLT can conduct price negotiations and issue a national 
recommendation. This research aims to evaluate which drugs the NLT have been 
appraising and what the final outcomes were. Methods: A systematic search for all 
publically available NLT recommendation documents up to 1stMay 2015 was under-
taken and the drug, date, indication and recommendation, was extracted. Results: 
50 appraisal documents were identified, 54% (27/50) of which were recommended, 
16% (8/50) received restricted recommendations, 16% (8/50) rejected and 14% (7/50) 
classified as other (deferred/unclear). However, it is important to note that many of 
the drugs that were approved were not recommended at list price with 41% (11/27) of 
recommendations being conditional on or following a discount (including confidential 
discounts) and 11% (3/27) being based on an agreed risk sharing agreement. 2 apprais-
als were for ZOSTAVAX in shingles, which was previously reimbursed but, based on 
more recent data, was now deemed to no longer offer benefits that justified its costs. 
44% (22/50) appraisals were for oncology drugs only 1 (2%) of which was rejected 
(YERVOY, but was accepted upon resubmission). ConClusions: The NLT appears to 
have successfully implemented a process where significant price pressure is exerted 
on companies with discounts being frequently secured without being too restrictive 
over coverage. Could giving other cost-utility HTA bodies negotiating powers help 
bridge the gap between cost-containment and broadening coverage?
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objeCtives: Health technology assessment (HTA) is not deeply rooted in Finnish 
hospitals despite of long lasting attempts to introduce it into routine decision mak-
ing. Both the processes and content of the HTA approach have been challenged. 
The EU-funded AdHopHTA project has provided good practices and new tools for 
hospital based HTA. The aim of this study is to smoothen the introduction of these 
new tools by examining the obstacles HTA currently faces in hospitals. Methods: 
Semi-structured group interviews in five public hospitals and two health care cen-
tres. Interviewees were clinical unit managers, division managers, and financial 
or procurement managers. Questions were related to the process of proposing, 
PHP38
druG PrIcInG reform In cHInA - ImPAct of tHe reform from A socIetAl 
PerPsectIve
Dong P1, Chen Y1, Jaros P2, Kornfeld A3, Yan J4, Toumi M5
1Pfizer Investment Co., Ltd., Beijing, China, 2Creativ-Ceutical, Cracow, Poland, 3Creativ-Ceutical, 
Paris, France, 4Creativ-Ceutical, London, UK, 5Université Aix Marseilles, Marseilles, France
objeCtives: Chinese drug pricing reform initiated on 1stJune 2015 aims to create 
incentives for efficient management of drug reimbursement budget. This study aimed 
to assess the potential impact of the reform from the societal perspective. Methods: 
We conducted a thorough research on the drug pricing reform using three Chinese 
databases (CNKI, Wanfang, Weipu), Chinese health authorities’ websites, relevant 
press releases, pharmaceutical blogs and discussion forums. This research was com-
plemented with targeted interviews with Chinese key opinion leaders representing 
authorities’ and prescribers’ perspectives. Results: The reform may include intro-
duction of internal reference pricing (IRP) for drugs with the same active ingredient 
and dosage form. Therapeutic interchangeability of drugs is an important issue in 
China. Interviewed opinion leaders consistently agree that there are discrepancies 
in terms of quality between imported drugs and some locally produced generics. 
Introduction of IRP may promote the use of cheaper generics with questionable qual-
ity. Increased use of low-quality drugs may affect patients’ safety and treatment 
outcomes, and in turn lead to undesired increase of expenditures in other health-
care sectors. It could also increase inequity between different income groups if, as a 
result of increased co-payment, only the wealthiest could afford high-quality drugs. 
Additionally, the reform should not be implemented in isolation. Creating effective 
incentives for cost-containment without affecting healthcare quality requires global, 
rather than ‘micro-level’ focus. With hospitals being the main distributor of out-
patient drugs in China and economically depending on profit generated from drugs 
sales, pricing reform should be comprehensive and address restructuring of hospitals’ 
financing and management system. ConClusions: Before introducing the reform 
on a big scale, all local specificities and challenges should be properly addressed, e.g. 
the issue of poor-quality drugs. International reference pricing policies cannot be 
transferred to China without being adjusted for local context. To be successful, the 
reform requires a comprehensive approach.
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objeCtives: Since 2009, the Chinese government has launched a global healthcare 
reform program aiming to control healthcare expenditure and increase the quality of 
care. As a part of this program, a new drug pricing reform was initiated starting 1stJune 
2015. The objective of this study is to describe the changing landscape of drug pricing 
policy in China. Methods: We conducted a thorough research on drug pricing reform 
using three Chinese databases (CNKI, Wanfang, Weipu), Chinese health authorities’ 
websites, relevant press releases, pharmaceutical blogs and discussion forums. The 
secondary research was complemented with targeted interviews with Chinese key 
opinion leaders representing authorities’ and prescribers’ perspectives. Results: With 
the current reform, the government attempts to replace its direct control over prices 
of reimbursable drugs by an indirect influence. Government pricing and government 
guided pricing are abolished for most drugs giving manufacturers more freedom to set 
market prices. However, an introduction of a form of internal reference pricing (IRP), 
named ”reimbursement standard” has been announced. To inform the best approach 
for implementation of this reform, China is currently running pilot projects in several 
cities. Sanming is piloting a form of IRP for drugs with the same active ingredient and 
dosage form; it set the reference price at the price of the cheapest generic. Shaoxing and 
Anhui are testing the concept of “2nd price negotiation” allowing hospitals to directly 
negotiate discounts with manufacturers using provincial government procurement 
prices as reimbursement caps. First results of Sanming and Shaoxing pilots have 
already been reported, proving their potential for drug budget saving. ConClusions: 
Many elements of the reform remain unclear and will likely depend on pilot projects 
outcomes. It seems that the Chinese government is considering adaptation of IRP poli-
cies commonly used by European countries. However, foreign pricing policies cannot 
be transferred to China without being adjusted for local characteristics.
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objeCtives: The Economic and Public Health Assessment Committee (CEESP) was 
introduced in 2012 as a specialised committee affiliated with the ‘Haute Autorité 
de Santé’ (HAS) in charge of providing health economic opinions. This research 
provides a forward-looking analysis of health economic assessment of pharma-
ceuticals in France and its impact on market access of drugs. It also provides likely 
directions of the future French HTA organisation and processes. Methods: We 
conducted a grey literature search on the HAS website and decision makers’ public 
presentations and comments. This search was complemented with a meeting with 
experts in market access and health economics, HTA and public health to discuss 
the current functioning and the likely future path of health economic assessment 
in France. The main issues that emerged from the search and the discussion were 
consolidated and analysed. Results: Major sources of inefficiencies appeared fol-
lowing the introduction of health economic assessment: (1) Duplication of work 
between the CEESP and the CT; (2) Resolution of divergent opinions between the 
CEEPS and the CEPS; (3) Confusion and conflicting information with respect to the 
